Millennium Pharmaceuticals to Acquire COR Therapeutics in $2.0 Billion Deal

Millennium Pharmaceuticals to Acquire COR Therapeutics in $2.0 Billion Deal

Firm News

On December 6, 2001, Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) announced that it had signed a definitive agreement to acquire COR Therapeutics, Inc. (Nasdaq: CORR) in a stock-for-stock exchange valued at $2.0 billion.

Millennium was advised by the following Hale and Dorr lawyers:

  • on corporate and securities matters, partners David Redlick, Jeff Stein and Jonathan Wolfman, junior partner Ken Lepage and associate Kris Spreen;
  • on intellectual property and licensing matters, partner Steven Singer, junior partner Michael Twomey and associates Jan Siok and Soojin Chung;
  • on tax matters, partner Rob Burke and associate Erika Buell;
  • on real estate matters, partner Keith Barnett;
  • on environmental matters, partner Rob Kirsch and associate Pat van der Voorn;
  • on employee benefits matters, partner Bill Schmidt; and
  • on immigration matters, partner Carolyn Fuchs.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.